278 related articles for article (PubMed ID: 15860572)
1. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
Hennan JK; Elokdah H; Leal M; Ji A; Friedrichs GS; Morgan GA; Swillo RE; Antrilli TM; Hreha A; Crandall DL
J Pharmacol Exp Ther; 2005 Aug; 314(2):710-6. PubMed ID: 15860572
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
Weisberg AD; Albornoz F; Griffin JP; Crandall DL; Elokdah H; Fogo AB; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles.
Rupin A; Martin F; Vallez MO; Bonhomme E; Verbeuren TJ
Thromb Haemost; 2001 Dec; 86(6):1528-31. PubMed ID: 11776323
[TBL] [Abstract][Full Text] [Related]
8. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
[TBL] [Abstract][Full Text] [Related]
9. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
[TBL] [Abstract][Full Text] [Related]
11. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
Br J Pharmacol; 2000 Oct; 131(4):858-64. PubMed ID: 11030738
[TBL] [Abstract][Full Text] [Related]
12. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
15. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
Lynch JJ; Cook JJ; Sitko GR; Holahan MA; Ramjit DR; Mellott MJ; Stranieri MT; Stabilito II; Zhang G; Lynch RJ
J Pharmacol Exp Ther; 1995 Jan; 272(1):20-32. PubMed ID: 7815334
[TBL] [Abstract][Full Text] [Related]
17. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
Abendschein DR; Baum PK; Verhallen P; Eisenberg PR; Sullivan ME; Light DR
J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis.
Jackson CV; Bailey BD; Shetler TJ
J Pharmacol Exp Ther; 2000 Dec; 295(3):967-71. PubMed ID: 11082430
[TBL] [Abstract][Full Text] [Related]
19. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
Roux S; Tschopp T; Baumgartner HR
J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
